Cubist Systematic Strategies’s Zevra Therapeutics ZVRA Stock Holding History

Cubist Systematic Strategies’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-88,414	Closed	-$779K	–	3657
2025 Q2	$779K	Buy	+88,414	New	+$717K	﹤0.01%	2066
2024 Q2	–	Sell	-468	Closed	-$2.71K	–	4179
2024 Q1	$2.71K	Buy	+468	New	+$2.88K	﹤0.01%	3566
2022 Q4	–	Sell	-19,771	Closed	-$123K	–	4650
2022 Q3	$123K	Sell	19,771 -10,168	-34%	-$57.6K	﹤0.01%	3949
2022 Q2	$134K	Buy	+29,939	New	+$136K	﹤0.01%	3865
2022 Q1	–	Sell	-24,373	Closed	-$212K	–	3807
2021 Q4	$212K	Buy	24,373 +9,427	+63%	+$84.1K	﹤0.01%	3001
2021 Q3	$139K	Buy	14,946 +3,543	+31%	+$35.7K	﹤0.01%	2675
2021 Q2	$146K	Buy	+11,403	New	+$123K	﹤0.01%	2648

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Cubist Systematic Strategies's ZVRA Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Zevra Therapeutics (ZVRA) in Q3 2025, closing a stake of 88,414 shares — an estimated $779K sold.

Cubist Systematic Strategies first reported a position in ZVRA in Q2 2021 and held it in 7 quarters. The position peaked at $779K in Q2 2025. 166 funds tracked by Wall St. Rank hold ZVRA as of Q3 2025.

Cubist Systematic Strategies reported no remaining Zevra Therapeutics position as of Q3 2025 after selling out during the quarter.
Cubist Systematic Strategies sold 88,414 Zevra Therapeutics shares in Q3 2025, an estimated $779K.
Cubist Systematic Strategies first reported a position in Zevra Therapeutics in Q2 2021 and held it in 7 quarters.
Cubist Systematic Strategies's Zevra Therapeutics position peaked at $779K in Q2 2025.
166 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.